FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules
| Autor: | Giovanni Butturini, Roberta Marciano, Luigi Formisano, Cataldo Bianco, Eleonora Mozzillo, Anna Chiara Carratù, Sabino De Placido, Isabella Frigerio, Francesca Foschini, Priscilla Cascetta, Pietro De Placido, Roberto Bianco, Fabiana Napolitano, Antonio Santaniello, Sabina Delcuratolo, Nicola Silvestris, P. Regi, Enrico Vasile, Alberto Servetto, Caterina Vivaldi |
|---|---|
| Přispěvatelé: | Foschini, F., Napolitano, F., Servetto, A., Marciano, R., Mozzillo, E., Carratu, A. C., Santaniello, A., De Placido, P., Cascetta, P., Butturini, G., Frigerio, I., Regi, P., Silvestris, N., Delcuratolo, S., Vasile, E., Vivaldi, C., Bianco, C., De Placido, S., Formisano, L., Bianco, R. |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Oncology
safety medicine.medical_specialty FOLFIRINOX lcsh:RC254-282 Metastasis gemcitabine pancreatic adenocarcinoma second line 03 medical and health sciences 0302 clinical medicine FOLFOX Internal medicine Pancreatic cancer Medicine 030212 general & internal medicine Original Research business.industry medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Gemcitabine Oxaliplatin Irinotecan 030220 oncology & carcinogenesis FOLFIRI business FOLFIRINOX gemcitabine pancreatic adenocarcinoma safety second line medicine.drug |
| Zdroj: | Therapeutic Advances in Medical Oncology Therapeutic Advances in Medical Oncology, Vol 12 (2020) |
| Popis: | Background: Pancreatic adenocarcinoma is the fourth leading cause of cancer-related death. In cases with metastasis, the combination of 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) or gemcitabine-based chemotherapy regimens are considered the standard of care. However, the optimal sequence of these regimens is unclear. Methods: This retrospective study initially evaluated 186 patients with locally advanced/metastatic pancreatic cancer at three Italian institutions between February 2013 and October 2019. All patients had progressed after receiving gemcitabine-based first-line chemotherapy and were subsequently offered second-line FOLFIRINOX, FOLFOX-6, or FOLFIRI treatment. This study evaluated progression-free survival (PFS), overall survival from the start of second-line treatment (OS2), overall survival from the start of first-line treatment (OS1), and safety outcomes. Results: A total of 77 patients received ⩾4 cycles of second-line chemotherapy and were considered eligible: 15 patients received FOLFIRINOX, 32 patients received FOLFOX-6, and 30 patients received FOLFIRI. The FOLFIRINOX group had median PFS of 26.29 weeks and median OS2 of 47.86 weeks, while the FOLFIRI group had median PFS of 10.57 weeks and median OS2 of 25.00 weeks ( p = 0.038). No significant differences were observed between the FOLFIRINOX and FOLFOX-6 groups in terms of PFS (26.29 weeks versus 23.07 weeks) or OS2 (47.86 weeks versus 42.00 weeks). The most common grade 3–4 toxicities were anemia, neutropenia, and thrombocytopenia, which occurred more frequently in the FOLFIRINOX and FOLFOX-6 groups. Conclusion: Relative to the FOLFIRI regimen, the FOLFIRINOX regimen had a favorable toxicity profile and better survival outcomes. No significant differences were observed relative to the FOLFOX-6 regimen. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|